EUVIMEDAtklāt EUVIMED
Open access

Risk factors and outcomes of Pneumocystis pneumonia in solid organ transplant recipients: Impact of posttransplant lymphoproliferative disorder

Zachary A Yetmar iD, Dustin Duffy, Byron H Smith iD, Holenarasipur R Vikram, Lisa Brumble, Andrew H Limper, Elena Beam iD

Clinical Transplantation · 2023

DOI: 10.1111/ctr.15021 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Zachary A Yetmar and 6 co-authors. Institution: Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Pneumonia, Pneumocystis, Kidney Transplantation, Pneumocystis carinii, Lymphoproliferative Disorders. Cited 13 times so far (Crossref); 27 references. The full text is freely available in PubMed Central. Funded by: NCATS NIH HHS, Mayo Clinic.

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) is a potentially fatal infection afflicting the immunocompromised population, including solid organ transplant (SOT) recipients. Several risk factors have been described; however, little is known regarding the risk of PJP in SOT recipients with posttransplant lymphoproliferative disorder (PTLD). METHODS: We performed a nested case-control study of SOT recipients diagnosed with PJP from 2000 to 2020. PJP was defined as positive microscopy or polymerase chain reaction testing with compatible symptoms and radiographic findings. Control patients were matched 2:1 by year of first transplant, first transplanted organ, transplant center, and sex. Multivariable conditional logistic regression was performed to test associations with PJP and Cox regression analyzed post-PJP outcomes. RESULTS: Sixty-seven PJP cases were matched to 134 controls. The most common transplant was kidney (55.2%). Fourteen patients had a history of PTLD, 12 of whom developed PJP. After adjusting for age, acute rejection, cytomegalovirus infection, PJP prophylaxis, and lymphopenia (lymphocyte count < .5 × 109 /L), PTLD was independently associated with PJP (OR 14.0, 95% CI 1.7-114.5; p = .014). Lymphopenia was also a significant association (OR 8.2, 95% CI 3.2-20.7; p < .001). PJP was associated with mortality within 90 days of diagnosis (p < .001), but not after 90 days (p = .317). PJP was also associated with 90-day death-censored renal allograft loss (p = .026). CONCLUSIONS: PTLD is independently associated with PJP after adjustment for recognized risk factors. This is likely influenced by PTLD-directed chemotherapy, particularly rituximab-containing regimens. PJP is associated with early mortality, but this effect is not persistent after 90 days. PJP prophylaxis should be considered in SOT recipients with PTLD.

Subjects

MeSH terms (MEDLINE)

Pneumonia, PneumocystisKidney TransplantationPneumocystis cariniiLymphoproliferative DisordersLymphopeniaHumansCase-Control StudiesRisk FactorsTransplant Recipients

Author keywords

PTLDPneumocystis jiroveciilymphopeniaopportunistic infectionprophylaxis

Authors and institutions

  • Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA.
  • Division of Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID profiles: Zachary A Yetmar, Byron H Smith, Elena Beam

Funding

  • NCATS NIH HHS
  • Mayo Clinic

Cite

APA

Yetmar, Z. A., Duffy, D., Smith, B. H., Vikram, H. R., Brumble, L., Limper, A. H., & Beam, E. (2023). Risk factors and outcomes of Pneumocystis pneumonia in solid organ transplant recipients: Impact of posttransplant lymphoproliferative disorder. Clinical Transplantation. https://doi.org/10.1111/ctr.15021

Vancouver

Yetmar ZA, Duffy D, Smith BH, Vikram HR, Brumble L, Limper AH, et al. Risk factors and outcomes of Pneumocystis pneumonia in solid organ transplant recipients: Impact of posttransplant lymphoproliferative disorder. Clinical Transplantation. 2023. doi:10.1111/ctr.15021

BibTeX
@article{Yetmar2023,
  author = {Yetmar, Zachary A and Duffy, Dustin and Smith, Byron H and Vikram, Holenarasipur R and Brumble, Lisa and Limper, Andrew H and Beam, Elena},
  title = {Risk factors and outcomes of Pneumocystis pneumonia in solid organ transplant recipients: Impact of posttransplant lymphoproliferative disorder},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.15021}
}
Start for free →